Skip to main content
AstraZenecaIn development

AstraZeneca India to Launch Datverzo as Q2 Revenue Rises 30%

Source: Autobound Signal API · 84 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca Pharma India Limited plans to launch Datverzo (datopotamab deruxtecan) in India in November 2026.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

AstraZeneca Pharma India Limited will launch Datverzo (datopotamab deruxtecan), a targeted therapy for advanced HR-positive, HER2-negative breast cancer, in India in November 2026, the company told stock exchanges on 7 November 2026. The update came two days after the drugmaker reported a 30.4% rise in Q2 FY27 revenue to ₹729 crore. In its exchange intimation, the company said the Drugs Controller General of India (DCGI) granted Datverzo import and market permission in Form CT-20, which it had disclosed on 17 December 2025. Commercial launch will now follow this month. Datverzo is approved for adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+ or IHC 2+/ISH-negative) who have already received endocrine-based therapy and chemotherapy for advanced disease. The filing did not disclose pricing. The launch adds to an active period for oncology pricing in India. Trade margin caps on 137 anti-cancer drugs take effect on 9 November, as covered in our report on cancer drug price cuts saving ₹3,502 crore a year. The company announced its results for the July–September 2026 quarter on 5 November 2026: The company said growth came from its oncology, biopharmaceuticals and rare disease portfolios. Results also included exceptional items linked to the closure of its Bengaluru...

Keep reading with a free account

The rest of this article, and every signal for AstraZeneca, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Datverzo
Takes effect
Nov 1, 2026
Location
India

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 8, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b5a80916-1fce-0110-1ccc-5bcdfd2c9ff3 returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "b5a80916-1fce-0110-1ccc-5bcdfd2c9ff3",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-08T02:04:34+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://ehealth.eletsonline.com/2026/11/astrazeneca-datverzo-india-launch/",
    "title": "AstraZeneca India to Launch Datverzo as Q2 Revenue Rises 30% - eHealth Magazine",
    "excerpt": "AstraZeneca Pharma India Limited will launch Datverzo (datopotamab deruxtecan), a targeted therapy for advanced HR-positive, HER2-negative breast cancer, in India in November 2026, the company told stock exchanges on 7 November 2026. The update came two days after the drugmaker reported a 30.4% rise in Q2 FY27 revenue to ₹729 crore. In its exchange intimation , the company said the Drugs Controller General of India (DCGI) granted Datverzo import and market permission in Form CT-20, which it had disclosed on 17 December 2025. Commercial launch will now follow this month. Datverzo is approved for adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+ or IHC 2+/ISH-negative) who have already received endocrine-based therapy and chemotherapy for advanced disease. The filing did not disclose pricing. The launch adds to an active period for oncology pricing in India. Trade margin caps on 137 anti-cancer drugs take effect on 9 November, as covered in our report on cancer drug price cuts saving ₹3,502 crore a year . The company announced its results for the July–September 2026 quarter on 5 November 2026: The company said growth came from its oncology, biopharmaceuticals and rare disease portfolios. Results also included exceptional items linked to the closure of its Bengaluru...",
    "product": "Datverzo",
    "summary": "AstraZeneca Pharma India Limited plans to launch Datverzo (datopotamab deruxtecan) in India in November 2026.",
    "location": "India",
    "planning": true,
    "image_url": "https://ehealth.eletsonline.com/wp-content/uploads/2026/11/astrazeneca-datverzo-launch.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "Datverzo",
      "full_text": "Datverzo (datopotamab deruxtecan)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-08T02:04:34Z",
    "location_data": [
      {
        "region": "Southern Asia",
        "country": "India",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-01",
    "article_sentence": "AstraZeneca Pharma India Limited will launch Datverzo (datopotamab deruxtecan), a targeted therapy for advanced HR-positive, HER2-negative breast cancer, in India in November 2026, the company told stock exchanges on 7 November 2026."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.